A single decoy oligodeoxynucleotides targeting multiple oncoproteins produces strong anticancer effects

Area of Science:

• Molecular Oncology
• Cancer Therapeutics
• Oligonucleotide Technology

Background:

• Cancer is a complex disease often requiring multifaceted therapeutic strategies.
• Single-agent therapies face limitations due to incomplete efficacy and dose-limiting side effects.
• Combination pharmacotherapy offers a promising approach for treating complex diseases like cancer.

Purpose of the Study:

• To develop and evaluate a novel complex decoy oligodeoxynucleotide (cdODN) technology for simultaneously targeting multiple transcription factors crucial in cancer.
• To assess the efficacy of cdODNs in inhibiting cancer-related gene expression, reducing cancer cell viability, and suppressing tumor growth in vivo.
• To explore the potential of cdODNs as a "one-drug, multiple-target" therapeutic strategy for diverse human cancers.

Main Methods:

• Design of decoy oligodeoxynucleotides (dODNs) targeting NF-kappaB, E2F, and Stat3 individually and a cdODN targeting all three concomitantly.
• Evaluation of cdODN effects on cancer-related gene expression using real-time reverse transcription-polymerase chain reaction.
• Assessment of cdODN impact on human cancer cell line viability and in vivo tumor growth in nude mouse models.

Main Results:

• The cdODN targeting NF-kappaB, E2F, and Stat3 demonstrated over a 2-fold enhancement in efficacy and a 2-order of magnitude increase in potency compared to individual dODNs or their combination.
• The cdODN exhibited an earlier onset of action and prolonged therapeutic effect.
• cdODNs effectively reduced the expression of target transcription factor-regulated genes, leading to significant cancer cell death and tumor growth inhibition.

Conclusions:

• The developed cdODN technology successfully mimics a drug cocktail approach by simultaneously targeting multiple oncogenic pathways.
• This innovative strategy offers enhanced efficacy, potency, and duration of action, paving the way for a "one-drug, multiple-target" therapy.
• cdODNs represent a promising platform for developing novel, effective treatments for a wide spectrum of human cancers.